-Company ramps up clinical diagnostics product development-
NEW HAVEN, Conn., July 17 /PRNewswire/ -- HistoRx, Inc., announced today that William C. Sullivan has joined the company as Senior Vice President, Diagnostic Operations. In this newly created position, Mr. Sullivan will be responsible for expanding the role of the company's diagnostics development process, overseeing the manufacture of HistoRx diagnostic products, and growing revenues associated with the clinical diagnostics services provided by HistoRx.
"I am delighted to have this opportunity to join HistoRx at such a promising time for the company," said Mr. Sullivan. "HistoRx has made impressive progress over the past several years in building a company that is well-poised with its unique AQUA(R) technology platform to capitalize on the tremendous opportunity that personalized medicine represents, powered by an expanding revenue-generating services operation. I look forward to leading the commercial laboratory operations for HistoRx's growing number of pharmaceutical and biotechnology customers as we focus concurrently on developing and commercializing our own line of HistoRx high-value clinical diagnostic products."
"The HistoRx management team, operations workforce, and Board of Directors are very pleased to have Bill join the company," said Rana Gupta, CEO of HistoRx. "Over the past year, we have moved the company rapidly toward our ultimate goal of introducing HistoRx-branded, FDA-approved, quantitative diagnostic tests that run on the proprietary HistoRx AQUA(R) technology. We believe these assays will offer significant improvements over currently available immunohistochemistry-based tests and drive standards-based market adoption of our technology. With his impressive diagnostics industry expertise combined with operations management experience, Bill will be a tremendous asset to HistoRx in leading our commercial laboratory operations and diagnostic product development."
Mr. Sullivan brings to HistoRx an accomplished management record, with more than 25 years of experience leading operations of technology-driven businesses in the in vitro diagnostics and medical devices industries. He was previously Vice President, Corporate Operations of Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.); prior to that, he served as Vice President, Diagnostic Manufacturing at Visible Genetics and as Vice President, Operations at the Nichols Institute Diagnostics (a subsidiary of Quest Diagnostics), among positions with other diagnostics and medical device companies. Mr. Sullivan also served as a consultant to diagnostics and medical device companies, specializing in manufacturing operations for FDA-regulated facilities and products. He earned a B.A. from The College of the Holy Cross in Worcester, Massachusetts and pursued graduate studies in the Department of Pathology at the University of Pennsylvania.
About HistoRx ( http://www.historx.com )
HistoRx, Inc. is a leader in the emerging field of tissue-based
diagnostic products for targeted patient treatment. HistoRx is developing
and commercializing novel diagnostic products and services based on the
company's pioneering AQUA(R) tissue biomarker analysis technology, which
provides exceptional measurement and localization of protein biomarkers in
their natural context within tissue. The proprietary AQUA(R) technology is
the first platform capable of measuring biomarker concentration with
subcellular resolution to generate more precise, efficient, and
cost-effective answers about the safety and effectiveness of new
therapeutics in development as well as enable the development of companion
diagnostic tests for targeted therapies. HistoRx services are used by
pharmaceutical and biotechnology companies throughout discovery research,
preclinical studies, and clinical drug development. HistoRx also develops
companion diagnostic products that are linked to partners' drug candidates
in development to predict therapeutic outcome, which HistoRx will co-market
with its partners' targeted therapeutics. These partnerships provide the
basis for HistoRx to pursue internal programs to develop proprietary in
vitro diagnostics that offer substantial improvements in treatment
decision-making and patient outcomes compared with existing
|SOURCE HistoRx, Inc.|
Copyright©2008 PR Newswire.
All rights reserved